Vector Labs Ab04906-3.3 Anti-TNF alpha [hTNF40 (Certolizumab)], Mouse IgG2b, Fc Silent™, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: hTNF40 (Certolizumab)
Heavy Chain Modification: Fc Silent™
Synonyms: TNF-α; TNFα; TNF; TNFA; TNFSF; Tumor necrosis factor; Cachectin; TNFalpha; TNF-alpha; Tumor necrosis factor ligand superfamily member 2; TNF-a; TNFa; CDP870; PHA-738144; CIMZIA
Amount: 100 μg
Application Codes Clone: Crystallography; Therapeutic; in vivo; in vitro
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: Fab
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This is a reformatted mouse IgG2b Fc Silent™ antibody, based on the original mouse format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody binds human TNF-alpha. In particular, the epitope is mostly located in the DE loop and GH loop regions of TNFα. Further, several residues on the epitope of are also involved in the TNFα–TNFR interaction.
Application Notes: The PEGylated Fab fragment of the antibody has been approved by the FDA as a biologic against TNFα. The original format of the antibody was used for in vitro and in vivo studies, where it showed to neutralize the activity of TNFα. Further, the antibody was effective and well tolerated by patients with RA (Choy et al, 2002; PMID: 12364632). The structure of Fab fragment of the antibody in complex with human TNFα was determined. The binding affinity of the Fab fragment to TNFα was measured by surface plasmon resonance (Kd= 0.2 pM) (Lee et al., 2017; PMID: 28124979). The specificity of the original format of the antibody was confirmed by ELISA analysis (US7012135). The original format of the antibody bound and neutralised both soluble and membrane-bound forms of TNFα. The pharmacokinetic properties of the PEGylate Fab fragments in vivo resulted in a half-life of 14 days. Isothermal titration calorimetry data showed that the original format of the antibody bound to 2.9 monomers in a TNFα trimer at saturation. The antibody was employed in in vivo studies in rats, primates and humans. Several clinical trials have also been conducted to examine the efficacy and tolerability of the original format of the antibody in patients with CD, RA and psoriasis (Filipovica et al., 2009).

Product Class:	Purified
Clone ID:	hTNF40 (Certolizumab)
Heavy Chain Modification:	Fc Silent™
Synonyms:	TNF-α; TNFα; TNF; TNFA; TNFSF; Tumor necrosis factor; Cachectin; TNFalpha; TNF-alpha; Tumor necrosis factor ligand superfamily member 2; TNF-a; TNFa; CDP870; PHA-738144; CIMZIA
Amount:	100 μg
Application Codes Clone:	Crystallography; Therapeutic; in vivo; in vitro
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	Fab
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This is a reformatted mouse IgG2b Fc Silent™ antibody, based on the original mouse format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody binds human TNF-alpha. In particular, the epitope is mostly located in the DE loop and GH loop regions of TNFα. Further, several residues on the epitope of are also involved in the TNFα–TNFR interaction.
Application Notes:	The PEGylated Fab fragment of the antibody has been approved by the FDA as a biologic against TNFα. The original format of the antibody was used for in vitro and in vivo studies, where it showed to neutralize the activity of TNFα. Further, the antibody was effective and well tolerated by patients with RA (Choy et al, 2002; PMID: 12364632). The structure of Fab fragment of the antibody in complex with human TNFα was determined. The binding affinity of the Fab fragment to TNFα was measured by surface plasmon resonance (Kd= 0.2 pM) (Lee et al., 2017; PMID: 28124979). The specificity of the original format of the antibody was confirmed by ELISA analysis (US7012135). The original format of the antibody bound and neutralised both soluble and membrane-bound forms of TNFα. The pharmacokinetic properties of the PEGylate Fab fragments in vivo resulted in a half-life of 14 days. Isothermal titration calorimetry data showed that the original format of the antibody bound to 2.9 monomers in a TNFα trimer at saturation. The antibody was employed in in vivo studies in rats, primates and humans. Several clinical trials have also been conducted to examine the efficacy and tolerability of the original format of the antibody in patients with CD, RA and psoriasis (Filipovica et al., 2009).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews